Get startedLog in
    Picture of Xlife Sciences AG logo

    XLS — Xlife Sciences AG Cashflow Statement

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Xlife Sciences AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line53.38.789.2728.7-27.1
    Depreciation
    Non-Cash Items-48.3-28.2-20.4-42.1-15.3
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-9.41-1.25-4.72-3.1213.2
    Change in Accounts Receivable
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Taxes Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-4.32-4.610.172-0.422-0.903
    Capital Expenditures-1.21-0.08-0.041-0.012-0.372
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-5.82-1.6-0.973-3.99-1.14
    Acquisition of Business
    Sale/Maturity of Investment
    Purchase of Investments
    Change in Net Intangibles
    Other Investing Cash Flow
    Cash from Investing Activities-7.03-1.68-1.01-4-1.52
    Financing Cash Flow Items-0.764-0.456-0.119-0.109-0.109
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities8.64.560.8294.32.72
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-2.75-1.74-0.002-0.120.305